Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
Mihael Hristos Polymeropoulos, the President and CEO of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), recently purchased 10,000 shares of the company’s common stock. The transaction, which took place on February 28, 2025, was executed at a price of $4.76 per share, amounting to a total value of $47,600. According to InvestingPro data, the company maintains impressive gross profit margins of 94.31% and holds more cash than debt on its balance sheet. The stock currently appears undervalued based on InvestingPro’s Fair Value analysis. Following this acquisition, Polymeropoulos now holds 2,361,730 shares directly. This move reflects his continued investment in the company, where he also serves as Chairman of the Board. While the company reported negative earnings in the last twelve months, InvestingPro analysis indicates net income is expected to grow this year. Discover more insights about insider trading patterns and 6 additional ProTips with an InvestingPro subscription.
In other recent news, Vanda Pharmaceuticals reported its fourth-quarter 2024 earnings, surpassing expectations with an earnings per share of -$0.08, compared to the forecasted -$0.17. The company also reported a revenue of $53.2 million, exceeding the forecast of $51.23 million. Following these results, H.C. Wainwright raised its price target for Vanda Pharmaceuticals to $20.00, maintaining a Buy rating. Cantor Fitzgerald also reiterated its Overweight rating and $13.00 price target, citing optimism for Vanda’s commercial trajectory by the end of 2025.
Additionally, Vanda Pharmaceuticals announced the development of a novel antisense oligonucleotide therapeutic, VCA-894A, for Charcot-Marie-Tooth disease Type 2S, which has received orphan designation from the FDA. The company also disclosed changes to its executive compensation, including adjustments to annual bonuses and base salaries, following a review by the Compensation Committee. These developments reflect Vanda Pharmaceuticals’ ongoing efforts to align its strategies with industry standards and investor expectations.
Furthermore, Vanda Pharmaceuticals has set its 2025 revenue guidance between $210 million and $250 million, indicating an approximate 16% year-over-year growth to the midpoint. Analysts at H.C. Wainwright project 2025 revenue to reach $225 million, with expectations for sequential revenue increases throughout the year. These projections are based on the anticipated adoption of Fanapt for bipolar disorder treatment and continued market penetration for Ponvory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.